인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
DBpia AI
AI 에이전트
AI 아이디어
AI 리더
AI 뷰어
Citeasy
크롬 서지관리 다운로드
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2009.1
- 수록면
- 227 - 233 (7page)
이용수
초록· 키워드
Purpose: Capecitabine (XelodaⓇ), which is a systemic prodrug of 5-fluorouracil, can be used in oral formulation for treatment
of advanced colorectal cancer as a 1st line or an alternative modality to I.V. 5-fluorouracil-based chemotherapy. One of the
most common side effects of this drug is hand-foot syndrome (HFS), palmar-plantar erythrodysesthesia syndrome. We planned
this study to clarify the incidence and the clinical course of severe hand-foot syndrome (WHO classification, grade 3 or 4)
following capecitabine monotherapy for adjuvant treatment of colorectal cancer.
Methods: From August 2006 to August 2008, 45 colorectal cancer patients were treated with capecitabine, 1,250 mg/m2,
orally administered twice daily for 2 wk, followed by 1 wk of rest, given as 3-wk cycles. Seven of them discontinued the drug
within 3rd cycle due to poor performance status, gastrointestinal troubles, or other causes. We retrospectively analyzed the
remaining 38 patients’ medical records and defined the incidence and the clinical course of HFS.
Results: Of the 38 patients, 17 (44.7%) suffered severe HFS after capecitabine monotherapy. Of those 17, 5 (29.4%) had
severe symptoms after the 1st chemotherapy cycle, and 14 patients (82.4%) had severe symptoms within the 4th cycle.
Three of the 14 female and 14 of the 24 male patients complained of severe HFS, showing a statistical male predominance (P=
0.043). Eventually, we had to decrease capecitabine to 75% of the daily dose in 12 patients and to 50% in one patient, and
to discontinue its use in 4 patients.
Conclusion: Capecitabine monotherapy very frequently provokes severe HFS, especially in the early cycles of chemotherapy
and in males.
상세정보 수정요청해당 페이지 내 제목·저자·목차·페이지정보가 잘못된 경우 알려주세요!
목차
등록된 정보가 없습니다.
참고문헌
참고문헌 신청최근 본 자료
